EUVIMEDEUVIMED entdecken
Crossref

Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway

Wenfei Yu, Guoliang Yin, Suwen Chen, Xin Zhang, Decheng Meng, Linya Wang, Hongshuai Liu, Wenying Jiang, Yuqing Sun, Fengxia Zhang

International Immunopharmacology · 2024-09 · 138 · 112581

DOI: 10.1016/j.intimp.2024.112581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-09. Verfasst von Wenfei Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shandong University of Traditional Chinese Medicine, Jinan 250013, People's Republic of China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Signal Transduction, Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Science and Technology Development Plan of Shandong Province, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-associated fatty liver disease (MAFLD) is one of the most common liver diseases worldwide; however, its pathogenesis and treatment methods have not been perfected. NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) is a promising therapeutic target for MAFLD. Diosgenin (DG) is a natural compound that was identified in a traditional Chinese herbal medicine, which has pharmacological effects, such as anti-inflammatory, antioxidant, hepatoprotective, and hypolipidemic activities. In this study, we examined the effects and molecular mechanisms of DG on MAFLD in vitro and in vivo. We established a rat model by administering a high-fat diet (HFD). We also generated an in vitro MAFLD model by treating HepG2 cells with free fatty acids (FFAs). The results indicated that DG attenuated lipid accumulation and liver injury in both in vitro and in vivo models. DG downregulated the expression of NLRP3, apoptosis-associated speckle-like protein (ASC), cysteinyl aspartate specific proteinase-1 (caspase-1), gasdermin D (GSDMD), GSDMD-n, and interleukin-1β (IL-1β). In addition, we silenced and overexpressed NLRP3 in vitro to determine the effects of DG on antiMAFLD. Silencing NLRP3 enhanced the effect of DG on the treatment of MAFLD, whereas NLRP3 overexpression reversed its beneficial effects. Taken together, the results show that DG has a favorable effect on attenuating MAFLD through the hepatic NLRP3 inflammasome-dependent signaling pathway. DG represents a natural NLRP3 inhibitor for the MAFLD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesSignal TransductionLiverNon-alcoholic Fatty Liver DiseaseRats, Sprague-DawleyDiosgeninAnimalsHumansMaleHep G2 CellsRatsDiet, High-FatDisease Models, AnimalAnti-Inflammatory Agents

Stichwörter der Autor:innen

DiosgeninHepG2MAFLDNLRP3 inflammasomeTCTG

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNlrp3 protein, ratDiosgeninAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Shandong University of Traditional Chinese Medicine, Jinan 250013, People's Republic of China.
  • Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, People's Republic of China. Electronic address: fxzhang0987@163.com.

Förderung

  • Science and Technology Development Plan of Shandong Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Yu, W., Yin, G., Chen, S., Zhang, X., Meng, D., Wang, L., Liu, H., Jiang, W., Sun, Y., & Zhang, F. (2024). Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway. International Immunopharmacology, 138, 112581. https://doi.org/10.1016/j.intimp.2024.112581

Vancouver

Yu W, Yin G, Chen S, Zhang X, Meng D, Wang L, et al. Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway. International Immunopharmacology. 2024;138:112581. doi:10.1016/j.intimp.2024.112581

BibTeX
@article{Yu2024,
  author = {Yu, Wenfei and Yin, Guoliang and Chen, Suwen and Zhang, Xin and Meng, Decheng and Wang, Linya and Liu, Hongshuai and Jiang, Wenying and Sun, Yuqing and Zhang, Fengxia},
  title = {Diosgenin attenuates metabolic-associated fatty liver disease through the hepatic NLRP3 inflammasome-dependent signaling pathway},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {138},
  pages = {112581},
  doi = {10.1016/j.intimp.2024.112581}
}
Kostenlos starten →